COLL Collegium Pharmaceutical Inc.

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Conference Call Information 

To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2024 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: . The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contact:

Christopher James, M.D.

Vice President, Investor Relations

Media Contact:

Marissa Samuels

Vice President, Corporate Communications



EN
25/04/2024

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces Authorized Generic Agreement with Hikma Pharmaceut...

Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta® ER (“th...

April 29, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report First Quarter 2024 Financial Results on May 9, 202...

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024 STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877...

April 25, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.6...

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 (the “Notes”) (CUSIP No. 19459JAA2; ISIN No. US19459JAA25) for redemption on Friday, June 14, ...

April 11, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in 23rd Annual Needham Virtual Healthcare Con...

Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference STOUGHTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference being held virtually from April 8-11, 2024. Details of the event are as follows:Fireside Chat Date and Time: Wednesday, April 10, 2024, at 3:45 p.m. ET The fireside chat will be webcast liv...

April 3, 2024 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 46.42
SHAK Shake Shack In...
XBIT XBIOTECH ... (+32)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

SHAK SHAKE SHACK INC. CLASS A
XBIT XBIOTECH
UFPT UFP TECHNOLOGIES
TRIP TRIPADVISOR INC.
TPH TRI POINTE HOMES INC.
PSX PHILLIPS 66
MTRX MATRIX SERVICE COMPANY
MSA MSA SAFETY INC.
MRK MERCK & CO. INC.
ISRG INTUITIVE SURGICAL INC.
HUBB HUBBELL INCORPORATED CLASS B
GPK GRAPHIC PACKAGING HOLDING COMPANY
FRPT FRESHPET INC
FANG DIAMONDBACK ENERGY INC.
DY DYCOM INDUSTRIES INC.
COLL COLLEGIUM PHARMACEUTICAL INC.
AL AIR LEASE CORPORATION CLASS A
ALV ALLIANZ SE
GBL GAMCO INVESTORS
CW CURTISS-WRIGHT CORPORATION
MPC. MADISON PACIFIC PROPERTIES INC. CL B
ELY CALLAWAY GOLF COMPANY
TG TREDEGAR CORP.
TAYD TAYLOR DEVICES INC.
HWKN HAWKINS INC.
FSTR L.B. FOSTER CO.
TEC TECHNIPFMC PLC
STRA STRATEGIC EDUCATION INC.
MRVI MARAVAI LIFESCIENCES HOLDINGS
SMLP SUMMIT MIDSTREAM PARTNERS
SGC ONTO INNOVATION INC.
SG CAPITAL PUBLIC COMPANY LIMITED
03/25/24 March 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch